Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists launch biobank to track early signs of PKD

NCT ID NCT02936791

First seen Apr 28, 2026 · Last updated Jun 11, 2026 · Updated 7 times

Summary

This study gathers blood and urine samples from 250 people with early-stage polycystic kidney disease (PKD), their healthy family members, and volunteers without kidney disease. The goal is to create a biobank that helps researchers find early markers of kidney cyst growth. This knowledge could improve how new treatments are developed and tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYSTIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Mercy Hospital

    RECRUITING

    Kansas City, Missouri, 64108, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

    Contact

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.